ExeGi Pharma

Executive Summary

ExeGi Pharma is a privately held, commercial-stage biotechnology company focused on developing and commercializing live biotherapeutic products and high-potency probiotics based on microbiome science. Based in Rockville, Maryland, the company leverages its expertise to address unmet medical needs in gastrointestinal and other chronic diseases. ExeGi's lead commercial product is Visbiome, a high-potency, multi-strain probiotic that is available over the counter and also used in clinical settings for conditions such as ulcerative colitis and pouchitis. Beyond its commercial probiotic, ExeGi has a pipeline of novel live biotherapeutic candidates targeting inflammatory bowel disease, irritable bowel syndrome, and other indications, utilizing its proprietary formulation and manufacturing capabilities. As an approved-stage company, ExeGi has demonstrated the ability to bring products to market and generate revenue, though it remains private and does not disclose financials. The company's competitive advantage lies in its scientifically validated strains and clinical evidence supporting its probiotic formulations, positioning it well in the growing microbiome therapeutics market. However, as a private entity, near-term visibility into pipeline progress is limited, and the company faces competition from larger probiotics and biotherapeutics players.

Upcoming Catalysts (preview)

• Q4 2026Potential FDA approval or expanded indication for a live biotherapeutic candidate (e.g., for ulcerative colitis)40% success
• Q2 2026Announcement of a strategic partnership or licensing deal with a larger pharmaceutical company for commercialization or co-development50% success
• Q3 2026Publication of positive clinical trial data for a GI indication (e.g., IBS or pouchitis) in a peer-reviewed journal or presentation at a major medical conference60% success